RxDoctor Payments Data

Winston Chung, MD

Internal Medicine · Los Alamitos, CANPI 1851322085

Payments from drug & device makers

$1,420in general payments, 2019–2025

Across 58 payments — averaging $24.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$251
  • AbbVie$182
  • Alkermes, Inc.$118
  • Karyopharm Therapeutics Inc.$108
  • Merck$95
  • Electromed, Inc.$80
  • plus $586 from 16 others

What the payments were for

  • Food & beverage$1,420100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,420 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$303,407
Medicare patients
502
Services billed
3,680

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban310$204,508
JanuviaSitagliptin Phosphate68$73,649
JardianceEmpagliflozin39$40,700
ProliaDenosumab18$29,612
XareltoRivaroxaban25$28,611
TrulicityDulaglutide13$23,873
FarxigaDapagliflozin Propanediol18$22,132
TradjentaLinagliptin27$20,815
MyrbetriqMirabegron31$14,237
Atorvastatin Calcium679$9,062
LokelmaSodium Zirconium Cyclosilicate13$8,198
Levothyroxine Sodium451$6,387
Pantoprazole Sodium260$6,365
Pregabalin18$6,067
EntrestoSacubitril/Valsartan11$5,902

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$23$207,367330 claims
MerckJanuvia$95$73,64968 claims
AstraZenecaFarxiga, Lokelma$32$30,33131 claims
AmgenProlia$42$29,61218 claims
Johnson & JohnsonXarelto$251$28,61125 claims
Lilly USA, LLCTrulicity$61$23,87313 claims
AbbVieSynthroid$182$4,60669 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Los Alamitos

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →